Skip to main content
Advertisement
Advertisement

RDY

RDY logo

Dr. Reddy's Laboratories Limited - ADR

12.25
USD
Sponsored
-0.05
-0.41%
Sep 25, 15:59 UTC -4
Closed
exchange

Pre-Market

12.46

+0.21
+1.67%

RDY Earnings Reports

Positive Surprise Ratio

RDY beat 23 of 42 last estimates.

55%

Next Report

Date of Next Report
Oct 22, 2026
Estimate for Q2 27 (Revenue/ EPS)
$83.44B
/
$9.65
Implied change from Q1 27 (Revenue/ EPS)
+3.01%
/
+81.05%
Implied change from Q2 26 (Revenue/ EPS)
-5.49%
/
-40.32%

Dr. Reddy's Laboratories Limited - ADR earnings per share and revenue

On Jul 22, 2026, RDY reported earnings of 5.33 USD per share (EPS) for Q1 27, missing the estimate of 9.03 USD, resulting in a -40.99% surprise. Revenue reached 81.00 billion, compared to an expected 83.23 billion, with a -2.69% difference. The market reacted with a -9.39% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 3 analysts forecast an EPS of 9.65 USD, with revenue projected to reach 83.44 billion USD, implying an increase of 81.05% EPS, and increase of 3.01% in Revenue from the last quarter.
FAQ
For Q1 2027, Dr. Reddy's Laboratories Limited - ADR reported EPS of $5.33, missing estimates by -40.99%, and revenue of $81.00B, -2.69% below expectations.
The stock price moved down -9.39%, changed from $12.56 before the earnings release to $11.38 the day after.
The next earning report is scheduled for Oct 22, 2026.
Based on 3 analysts, Dr. Reddy's Laboratories Limited - ADR is expected to report EPS of $9.65 and revenue of $83.44B for Q2 2027.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement